80 related articles for article (PubMed ID: 22156358)
1. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
[TBL] [Abstract][Full Text] [Related]
2. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Eran Z; Zingariello M; Bochicchio MT; Bardelli C; Migliaccio AR
F1000Res; 2019; 8():. PubMed ID: 31583083
[TBL] [Abstract][Full Text] [Related]
3. How I treat transplant-eligible patients with myelofibrosis.
Kröger N; Wolschke C; Gagelmann N
Blood; 2023 Nov; 142(20):1683-1696. PubMed ID: 37647853
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and bone marrow fibrosis: novel immunotherapeutic targets.
Calledda FR; Malara A; Balduini A
Curr Opin Hematol; 2023 Nov; 30(6):237-244. PubMed ID: 37548363
[TBL] [Abstract][Full Text] [Related]
5. Successful Hematopoietic Cell Transplantation for Infantile Primary Myelofibrosis/VPS45 Deficiency: Case Report and Review of Literature.
Hashem H; Alnasser Y
J Clin Immunol; 2023 Jul; 43(5):907-909. PubMed ID: 36913133
[No Abstract] [Full Text] [Related]
6. Evidence creation for myelofibrosis: Challenges and opportunities.
Gupta V
Br J Haematol; 2024 Jan; 204(1):19-21. PubMed ID: 38083995
[TBL] [Abstract][Full Text] [Related]
7. Double, double, TP53, and trouble in myelofibrosis.
Krishnamurthy P
Blood; 2023 Jun; 141(23):2793-2795. PubMed ID: 37289476
[No Abstract] [Full Text] [Related]
8. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Wardhana ; Datau EA; Rotty LW; Haroen H
Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
10. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
11. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
13. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
